FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360851008> ?p ?o ?g. }

• W4360851008 endingPage "723" @default.
• W4360851008 startingPage "723" @default.
• W4360851008 abstract "An intranasal COVID-19 vaccine, DelNS1-based RBD vaccines composed of H1N1 subtype (DelNS1-nCoV-RBD LAIV) was developed to evaluate the safety and immunogenicity in healthy adults. We conducted a phase 1 randomized, double-blinded, placebo-controlled study on healthy participants, age 18–55 and COVID-19 vaccines naïve, between March and September 2021. Participants were enrolled and randomly assigned (2:2:1) into the low and high dose DelNS1-nCoV-RBD LAIV manufactured in chicken embryonated eggs or placebo groups. The low and high-dose vaccine were composed of 1 × 107 EID50/ dose and 1 × 107.7 EID50/ dose in 0.2 mL respectively. The placebo vaccine was composed of inert excipients/dose in 0.2 mL. Recruited participants were administered the vaccine intranasally on day 0 and day 28. The primary end-point was the safety of the vaccine. The secondary endpoints included cellular, humoral, and mucosal immune responses post-vaccination at pre-specified time-points. The cellular response was measured by the T-cell ELISpot assay. The humoral response was measured by the serum anti-RBD IgG and live-virus neutralizing antibody against SARS-CoV-2. The saliva total Ig antibody responses in mucosal secretion against SARS-CoV-2 RBD was also assessed. Twenty-nine healthy Chinese participants were vaccinated (low-dose: 11; high-dose: 12 and placebo: 6). The median age was 26 years. Twenty participants (69%) were male. No participant was discontinued due to an adverse event or COVID-19 infection during the clinical trial. There was no significant difference in the incidence of adverse events (p = 0.620). For the T-cell response elicited after full vaccination, the positive PBMC in the high-dose group increased to 12.5 SFU/106 PMBC (day 42) from 0 (baseline), while it increased to 5 SFU/106 PBMC (day 42) from 2.5 SFU/106 PBMC (baseline) in the placebo group. The high-dose group showed a slightly higher level of mucosal Ig than the control group after receiving two doses of the vaccine (day 31, 0.24 vs. 0.21, p = 0.046; day 56 0.31 vs. 0.15, p = 0.45). There was no difference in the T-cell and saliva Ig response between the low-dose and placebo groups. The serum anti-RBD IgG and live virus neutralizing antibody against SARS-CoV-2 were undetectable in all samples. The high-dose intranasal DelNS1-nCoV-RBD LAIV is safe with moderate mucosal immunogenicity. A phase-2 booster trial with a two-dose regimen of the high-dose intranasal DelNS1-nCoV-RBD LAIV is warranted." @default.
• W4360851008 created "2023-03-25" @default.
• W4360851008 creator A5011168335 @default.
• W4360851008 creator A5019087640 @default.
• W4360851008 creator A5019269561 @default.
• W4360851008 creator A5024396216 @default.
• W4360851008 creator A5028000897 @default.
• W4360851008 creator A5030509173 @default.
• W4360851008 creator A5030850160 @default.
• W4360851008 creator A5031403461 @default.
• W4360851008 creator A5031848511 @default.
• W4360851008 creator A5033103064 @default.
• W4360851008 creator A5034244519 @default.
• W4360851008 creator A5039924631 @default.
• W4360851008 creator A5045545412 @default.
• W4360851008 creator A5048732806 @default.
• W4360851008 creator A5056304995 @default.
• W4360851008 creator A5060002817 @default.
• W4360851008 creator A5063432237 @default.
• W4360851008 creator A5064519227 @default.
• W4360851008 creator A5066110089 @default.
• W4360851008 creator A5069394692 @default.
• W4360851008 creator A5077357809 @default.
• W4360851008 creator A5081074507 @default.
• W4360851008 creator A5083283698 @default.
• W4360851008 creator A5086047401 @default.
• W4360851008 creator A5091123398 @default.
• W4360851008 date "2023-03-24" @default.
• W4360851008 modified "2023-10-18" @default.
• W4360851008 title "A Phase 1, Randomized, Double-Blinded, Placebo-Controlled and Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the Intranasal DelNS1-nCoV-RBD LAIV for COVID-19 in Healthy Adults" @default.
• W4360851008 cites W2013645764 @default.
• W4360851008 cites W2884893672 @default.
• W4360851008 cites W2974248066 @default.
• W4360851008 cites W3025320502 @default.
• W4360851008 cites W3049654234 @default.
• W4360851008 cites W3092050672 @default.
• W4360851008 cites W3109360305 @default.
• W4360851008 cites W3113115421 @default.
• W4360851008 cites W3180638661 @default.
• W4360851008 cites W3184287782 @default.
• W4360851008 cites W3187192250 @default.
• W4360851008 cites W3202826390 @default.
• W4360851008 cites W4200131705 @default.
• W4360851008 cites W4205810842 @default.
• W4360851008 cites W4206997616 @default.
• W4360851008 cites W4210308999 @default.
• W4360851008 cites W4210412299 @default.
• W4360851008 cites W4211106360 @default.
• W4360851008 cites W4221068248 @default.
• W4360851008 cites W4225699254 @default.
• W4360851008 cites W4225854071 @default.
• W4360851008 cites W4226321964 @default.
• W4360851008 cites W4304112065 @default.
• W4360851008 cites W4307441048 @default.
• W4360851008 doi "https://doi.org/10.3390/vaccines11040723" @default.
• W4360851008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37112634" @default.
• W4360851008 hasPublicationYear "2023" @default.
• W4360851008 type Work @default.
• W4360851008 citedByCount "0" @default.
• W4360851008 crossrefType "journal-article" @default.
• W4360851008 hasAuthorship W4360851008A5011168335 @default.
• W4360851008 hasAuthorship W4360851008A5019087640 @default.
• W4360851008 hasAuthorship W4360851008A5019269561 @default.
• W4360851008 hasAuthorship W4360851008A5024396216 @default.
• W4360851008 hasAuthorship W4360851008A5028000897 @default.
• W4360851008 hasAuthorship W4360851008A5030509173 @default.
• W4360851008 hasAuthorship W4360851008A5030850160 @default.
• W4360851008 hasAuthorship W4360851008A5031403461 @default.
• W4360851008 hasAuthorship W4360851008A5031848511 @default.
• W4360851008 hasAuthorship W4360851008A5033103064 @default.
• W4360851008 hasAuthorship W4360851008A5034244519 @default.
• W4360851008 hasAuthorship W4360851008A5039924631 @default.
• W4360851008 hasAuthorship W4360851008A5045545412 @default.
• W4360851008 hasAuthorship W4360851008A5048732806 @default.
• W4360851008 hasAuthorship W4360851008A5056304995 @default.
• W4360851008 hasAuthorship W4360851008A5060002817 @default.
• W4360851008 hasAuthorship W4360851008A5063432237 @default.
• W4360851008 hasAuthorship W4360851008A5064519227 @default.
• W4360851008 hasAuthorship W4360851008A5066110089 @default.
• W4360851008 hasAuthorship W4360851008A5069394692 @default.
• W4360851008 hasAuthorship W4360851008A5077357809 @default.
• W4360851008 hasAuthorship W4360851008A5081074507 @default.
• W4360851008 hasAuthorship W4360851008A5083283698 @default.
• W4360851008 hasAuthorship W4360851008A5086047401 @default.
• W4360851008 hasAuthorship W4360851008A5091123398 @default.
• W4360851008 hasBestOaLocation W43608510081 @default.
• W4360851008 hasConcept C126322002 @default.
• W4360851008 hasConcept C133239900 @default.
• W4360851008 hasConcept C142724271 @default.
• W4360851008 hasConcept C159654299 @default.
• W4360851008 hasConcept C197934379 @default.
• W4360851008 hasConcept C203014093 @default.
• W4360851008 hasConcept C203092338 @default.
• W4360851008 hasConcept C204787440 @default.
• W4360851008 hasConcept C22070199 @default.
• W4360851008 hasConcept C27081682 @default.
• W4360851008 hasConcept C2776090121 @default.
• W4360851008 hasConcept C2779053233 @default.

• next